Renovaro (FRA:2Q5) Current Accrued Expense : €3.45 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Renovaro Current Accrued Expense?

Renovaro's Current Accrued Expense for the quarter that ended in Mar. 2024 was €3.45 Mil.

Renovaro's quarterly Current Accrued Expense declined from Sep. 2023 (€0.75 Mil) to Dec. 2023 (€0.72 Mil) but then increased from Dec. 2023 (€0.72 Mil) to Mar. 2024 (€3.45 Mil).

Renovaro's annual Current Accrued Expense declined from Jun. 2021 (€0.98 Mil) to Jun. 2022 (€0.98 Mil) and declined from Jun. 2022 (€0.98 Mil) to Jun. 2023 (€0.67 Mil).

Renovaro Current Accrued Expense Historical Data

The historical data trend for Renovaro's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Current Accrued Expense Chart

Renovaro Annual Data

Trend

Mar13

Dec14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Current Accrued Expense

Get a 7-Day Free Trial

0.30

0.42

0.98

0.67

Renovaro Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															0.56	0.67	0.75	0.72	3.45

Renovaro Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Renovaro Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Renovaro's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovaro (FRA:2Q5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (FRA:2Q5) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

RENB:USA 2Q5:Germany

Address

2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067

Website

https://www.enochianbio.com

Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.

Renovaro (FRA:2Q5) Headlines

No Headlines